ARS Pharmaceuticals (SPRY) Net Equity Issued and Repurchased (2020 - 2021)

ARS Pharmaceuticals (SPRY) posted Net Equity Issued and Repurchased of $54.8 million for Q4 2021, up 109712.0% sequentially from -$50000.0 in Q4 2020, and up 109712.0% YoY from N/an in Q4 2020.

ARS Pharmaceuticals (SPRY) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends

ARS Pharmaceuticals has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $54.8 million in Q4 2021.

  • Quarterly Net Equity Issued and Repurchased rose 109712.0% year-over-year to $54.8 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $174.4 million (up 13.76% YoY) and the FY2021 annual result came in at $54.8 million, down 64.26% from the prior year.
  • Net Equity Issued and Repurchased advanced to $54.8 million in Q4 2021 per SPRY's latest filing, from -$50000.0 in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $119.7 million in Q3 2020 and troughed at -$50000.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 ARS Pharmaceuticals 561.88 Mn 418.03 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 54.81 Mn
Dec 31, 2021 54.81 Mn
Dec 31, 2020 -50,000.00
Dec 31, 2020 -50,000.00
Sep 30, 2020 119.69 Mn
Sep 30, 2020 119.69 Mn
Jun 30, 2020 12.05 Mn
Jun 30, 2020 12.05 Mn
Mar 31, 2020 21.66 Mn
Mar 31, 2020 21.66 Mn